This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety of Testosterone Undecanoate i.m. in Hypogonadal Men

This study has been completed.
Information provided by:
University Hospital Muenster Identifier:
First received: March 26, 2007
Last updated: NA
Last verified: March 2007
History: No changes posted
Treatment of male hypogonadism by testosterone substitution has be monitored in terms of safety. This study relates to safety of a new long-acting preparation.

Condition Intervention Phase
Hypogonadism Drug: Testosterone Substitution by Testosterone Undecanoate i.m. Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Long-Term Intervention Phase 2 Study of Safety Aspects of Testosterone Undecanoate i.m. in Hypogonadal Men

Resource links provided by NLM:

Further study details as provided by University Hospital Muenster:

Primary Outcome Measures:
  • Prostate (size, PSA-level)
  • Erythropoeisis (Hemoglobin, Hematocrit)
  • Lipoproteins (HDL, LDL, Triglycerides)
  • Blood pressure
  • Pulse

Secondary Outcome Measures:
  • Possible changes of body mass index

Estimated Enrollment: 60
Study Start Date: April 1997
Study Completion Date: January 2007
Detailed Description:

A reliable form of androgen substitution therapy regarding kinetics, tolerance and restoration of androgenicity is paramount in hypogonadal men. Intramuscular injection of the long-acting ester testosterone undecanoate (TU) offers a new modality.

The objective is to assess safety of TU regarding metabolic and pharmacogenetic confounders in hypogonadal men treated with this new formulation.

This is a longitudinal prospective one-arm open intervention and observation trial. A minimum of 5 individual assessments is a prerequisite. Investigated modulators of safety parameters entering regression models are: nadir and/or delta total testosterone concentrations, body mass index (BMI), and age.

The setting Andrological outpatient department.


Ages Eligible for Study:   17 Years to 70 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Men presenting hypogonadism-related symptoms and desiring substitution therapy. Such symptoms are fatigue, loss of libido, depressiveness, change in body composition/weight, decreased physical performance, decrease in aggressive behaviour, disability to cope, decreased work performance, lack of androgenization. At least one of these symptoms has to be accompanied by low total testosterone levels (< 12 nmol / L).
  • All patients have to give written informed consent for the use of their data for scientific evaluation as approved by the Ethics Committee of the Medical Faculty, University of Muenster, Germany and the State Medical Board.

Exclusion Criteria:

  • Prostate Cancer
  • Breast Cancer
  • Desired Paternity
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00452322

Institute of Reproductive Medicine of the University Clinics
Muenster, Germany
Sponsors and Collaborators
University Hospital Muenster
Study Director: Eberhard Nieschlag, MD, PhD University Clinics Muenster, Germany
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00452322     History of Changes
Other Study ID Numbers: IRM 96/17
EK 78a/97Nie1
Study First Received: March 26, 2007
Last Updated: March 26, 2007

Keywords provided by University Hospital Muenster:

Additional relevant MeSH terms:
Gonadal Disorders
Endocrine System Diseases
Testosterone enanthate
Testosterone undecanoate
Testosterone 17 beta-cypionate
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Anabolic Agents processed this record on June 26, 2017